Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Izzi
P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Oncology in Clinical Practice
Oncology
174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors
Translational Lung Cancer Research
Oncology
